Neogap Therapeutics AB

https://www.neogap.se

LinkedIn: https://www.linkedin.com/company/neogap-ab

NEOGAP Therapeutics is a Swedish biotechnology company focused on developing personalised cancer immunotherapy using the patient’s cells. The therapy is based on the company’s two technologies, PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognise and attack the selected tumour-specific targets. NEOGAP is located at the Center for Molecular Medicine at the Karolinska Institute in Stockholm. *

	Start	2016-01-01 established
	Industry	EpiTCer® technology
	Industry 2	bioinformatics (biological software and databases)
	Person	Svensson, Samuel (Neogap Therapeutics 202305 CEO)

	Region	Stockholm
	Country	Sweden
	Street	Karolinska Universitetssjukhuset Center for Molecular Medicine
	City	17176 Stockholm
	Tel	+46-733-542194
		Address record changed: 2023-05-07

Basic data	Employees	n. a.

		* Document for »About Section«: Neogap Therapeutics AB. (5/4/23). "Press Release: Neogap and Cellerys Enter Collaboration Related to Phase II Study of a New Therapy for Multiple Sclerosis".

		Record changed: 2024-02-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Neogap Therapeutics AB

[1] Neogap Therapeutics AB. (5/4/23). "Press Release: Neogap and Cellerys Enter Collaboration Related to Phase II Study of a New Therapy for Multiple Sclerosis"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]